



Ocular Surface Infection and Antimicrobials

Guest Editors:

Prof. Dr. Mark Willcox

School of Optometry and Vision
Science, University of New South
Wales, Sydney, NSW 2052,
Australia

Prof. Dr. Fiona Stapleton

School of Optometry and Vision
Science, University of New South
Wales, Sydney, NSW, Australia

Dr. Debarun Dutta

Optometry and Vision Science
Research Group, Aston
University, Birmingham, UK

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Infection of the ocular surface can have devastating consequences if not appropriately treated with antimicrobials. The ocular surface can be infected by bacteria, fungi, viruses and protozoa. These infections can lead to blindness or evisceration of the globe. Treatment often needs to be fast, empirical and based on presentation of the disease. However, infection by different microbes can manifest similarly and so initial treatment may have to be changed. Furthermore, microbes causing infections are showing increasing resistance to antimicrobials. These delays can worsen outcomes.

This Special Issue seeks to examine the susceptibility of ocular surface isolates from different geographical areas to current and new antimicrobial agents. Clinical trials, observational studies, case series reports, laboratory studies, systematic reviews and meta-analyses providing new insights into the antibiotic treatment of ocular surface microbial infections are encouraged. Data on the effect of antimicrobial resistance to clinical outcome are especially encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi